was significantly lower in group B than in group A (group B, 86±33 U/kg; group A, 183±95 U/kg, Background. The effect of the adequacy of dialysis on the response to recombinant human erythropoietin P<0.0001).
Introduction least 3 months. Exclusion criteria included HBsAg and HIV positivity, need for blood transfusions or evidence of blood loss in the 3 months before the study, and The main pathogenetic factor causing anaemia in acute or chronic infections. Hct and haemoglobin (Hb) chronic renal failure is the reduced synthesis of erythrolevels were evaluated weekly for 4 weeks; TSAT, serum poietin ( Epo) by the diseased kidneys [1] . The introferritin, Kt/V, PCRn, serum albumin (sAlb), and duction of recombinant human Epo (rHuEpo) therapy weekly dose of rHuEpo were evaluated at the end of in the last 10 years has dramatically changed anaemia observation. No change in dialysis or therapy prescrip-treatment. Its great efficacy in correcting anaemia in a tion was made during the study.
dose-dependent manner has been demonstrated both Results. The results for the whole group of patients in the original [2] and subsequent clinical trials [3, 4] . were: Hct 35±1.2%, Hb 12.1±0.6 g/dl, TSAT 29± Many factors are known to blunt the optimal responseand membrane biocompatibility on the response to (CRP) , serum intact PTH (iPTH ), weekly rHuEpo rHuEpo therapy, we investigated the relationship dose/body weight.
between the dose of rHuEpo and the dose of dialysis Urea kinetic modelling ( UKM ) was performed mid-week in a group of 68 haemodialysis (HD) patients on at the start and at the end of the study. Samples for BUN stabilized rHuEpo therapy with adequate iron stores, were drawn from the arterial side of the AV fistula at the treated with bicarbonate dialysis and unsubstituted start, 15 min after the end, and at the beginning of the next cellulosic membranes. dialysis session and processed by auto analyser. The duration of each dialysis session, duration of the elapsed times between dialyses, intra-dialytic weight loss and inter-dialytic weight gain were recorded. All patients were anuric or very oliguric
Patients and methods
(daily urine volume <100 ml/24 h). The values for Kt/V and PCRn were the mean of the two tests performed at the start and at the end of observation. Although not recommended Sixty-eight uraemic patients (43 men, 25 women), mean age by the recently published European Best Practice Guidelines 65±15 years (range 20-89 years) on regular chronic HD for for the management of anaemia in patients with chronic 6-343 months (median 67 months) were selected from a total renal failure [11], we decided to evaluate Hb and Hct levels population of 167 patients treated at our Institution. All of in post-dialysis in order to minimize the differences due to them were treated by bicarbonate HD thrice weekly with hyperhydration. These parameters were performed weekly 1.3-1.8 m2 unsubstituted cellulosic membranes (Fresenius and determined by Coulter counter model STKS. iPTH was Hemoflow E 35; Bellco NT 1808). The duration of the determined by an immunoradiometric assay for intact paradialysis procedure ranged from 180 to 270 min (median thyroid hormone (Allegro, Nichols Institute, San Juan 240 min). Blood flow rate ranged from 250 to 350 ml/min Capistrano, CA, USA; normal values: 10-65 pg/ml ). Serum (median 300 ml/min). Dialysate flow rate was 500 ml/min. albumin concentrations were measured by nephelometric Dialysate fluid composition was sodium 140 mmol/l, potas-assay, other biochemical parameters were assayed by standsium 2-3 mmol/l, calcium 1. 
Exclusion criteria
C1 and C2 are BUN concentrations at the start and 15 min after the end of dialysis; C3 is the BUN concentration at the Refusal by the patient to participate, known blood dyscrasia beginning of the next dialysis; Td is the dialysis time; Tid is or haemoglobinopathy, micro or macrocytosis (mean the inter dialysis time. V1 is the volume of distribution of corpuscular volume <80 or >100 mm3), HIV and HBsAg urea at the end of dialysis; V2 is the volume of distribution positivity, treatment for any infection with drugs known to of urea at the beginning of the next dialysis session. affect erythropoiesis, including androgens and angiotensinconverting enzyme (ACE) inhibitors, systemic disease, neoplasia, cachexia. Patients were also excluded if any of the Statistics following events had occurred in the 3 months preceding the study: blood loss (gastrointestinal bleeding and/or blood loss All the data are expressed as mean±SD. Linear regression from the vascular access), blood transfusions, hospitaliza-analysis, multiple regression analysis and Student t test for tions, infection (fever and leukocytosis). unpaired data were adopted for statistical evaluation. The patients selected were all those that satisfied the Significant differences were defined by P<0.05. inclusion/exclusion criteria referred above.
The underlying renal diseases were: chronic glomerulonephritis in 11 patients, tubulointerstitial nephritis in 14, 12±0.6 g/dl, Hct 35±1.2% (range 31-39%), TSAT 29±10%, serum ferritin concentrations 204±98 ng/ml, Study protocol PCRn 1.11±0.28 g/kg BW/day, serum albumin concentrations 4.1±0.3 g/dl, CRP 7±2 mg/l, serum iPTH
Patients enrolled in the study were prospectively followed 189±142 pg/ml (range 11-490 pg/ml ). of dialysis adequacy and dialysis membrane very problematic. In order to separate the effect of dialysis adequacy per se from the effect of membrane biocomHct did not correlate with Kt/V (P=NS ), whereas patibility, we have selected a cohort of patients on rHuEpo dose and Kt/V were inversely correlated regular HD treatment with unsubstituted cellulosic (P<0.0001) (Figure 1) . membranes, on maintenance s.c. rHuEpo treatment Table 1 shows the results of the multiple regression with stable Hct levels targeted at 35% as recommended analysis. Considering the weekly rHuEpo dose as by the DOQI guidelines [17] . All of them were iron dependent variable, it was evident that the only para-replete, and with no known causes of resistance to meter that correlated with the rHuEpo dose was Kt/V. rHuEpo. Kt/V for the whole group of patients was Table 2 shows the results of the comparison of Hct 1.33±0.19, well above the minimum suggested dose and weekly rHuEpo dose after the division of the for dialysis adequacy [18] , and serum albumin concenpatients into two groups according to Kt/V values trations were 4.1±0.3 g/dl, indicating a good nutri-(group A, Kt/V ∏1.2; group B, Kt/VÁ1.4). Hct did tional status. Although all these clinical features were not differ between the two groups, while weekly satisfied, the rHuEpo doses needed to maintain the rHuEpo dose was significantly higher in patients in target Hct were widely distributed, ranging from 34 to group A compared with those in group B.
354 U/kg/week. There was no correlation between Kt/V and Hct, and this is not surprising because, in our study, Hct is showed that while Hct levels did not differ between the two groups, the weekly rHuEpo dose was significantly lower in patients with better Kt/V levels as ences. These authors showed that Hct and the dose of
dialysis, evaluated by the urea reduction ratio ( URR), were directly correlated. However, unlike our study,
patients were treated with a fixed dose of rHuEpo and rHuEpo dose 183±95 0.0001 86±33
Hct was an independent variable. In addition, a group ( U/kg/Week) of patients were assigned to standard ( URR=61%) or [20, 21] . 
